- Home
- DRMA vs BTAI Comparison
DRMA vs BTAI Comparison
Compare DRMA & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- BTAI
- Stock Information
- Founded
- DRMA 2014
- BTAI 2017
- Country
- DRMA United States
- BTAI United States
- Employees
- DRMA N/A
- BTAI N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- DRMA Health Care
- BTAI Health Care
- Exchange
- DRMA Nasdaq
- BTAI Nasdaq
- Market Cap
- DRMA 6.1M
- BTAI 6.6M
- IPO Year
- DRMA 2021
- BTAI 2018
- Fundamental
- Price
- DRMA $1.25
- BTAI $2.13
- Analyst Decision
- DRMA Strong Buy
- BTAI Buy
- Analyst Count
- DRMA 1
- BTAI 4
- Target Price
- DRMA $6.00
- BTAI $37.00
- AVG Volume (30 Days)
- DRMA 465.7K
- BTAI 279.4K
- Earning Date
- DRMA 03-20-2025
- BTAI 03-11-2025
- Dividend Yield
- DRMA N/A
- BTAI N/A
- EPS Growth
- DRMA N/A
- BTAI N/A
- EPS
- DRMA N/A
- BTAI N/A
- Revenue
- DRMA N/A
- BTAI $2,276,000.00
- Revenue This Year
- DRMA N/A
- BTAI $105.36
- Revenue Next Year
- DRMA N/A
- BTAI $46.93
- P/E Ratio
- DRMA N/A
- BTAI N/A
- Revenue Growth
- DRMA N/A
- BTAI 83.25
- 52 Week Low
- DRMA $1.00
- BTAI $2.10
- 52 Week High
- DRMA $7.62
- BTAI $56.00
- Technical
- Relative Strength Index (RSI)
- DRMA 52.68
- BTAI 28.68
- Support Level
- DRMA $1.00
- BTAI $2.18
- Resistance Level
- DRMA $1.28
- BTAI $2.60
- Average True Range (ATR)
- DRMA 0.09
- BTAI 0.44
- MACD
- DRMA 0.01
- BTAI -0.08
- Stochastic Oscillator
- DRMA 74.07
- BTAI 0.94
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.